We are live on ! Find out more
XBI icon

State Street SPDR S&P Biotech ETF

769 hedge funds and large institutions have $10.2B invested in State Street SPDR S&P Biotech ETF in 2024 Q3 according to their latest regulatory filings, with 88 funds opening new positions, 240 increasing their positions, 270 reducing their positions, and 73 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 73

17% more funds holding in top 10

Funds holding in top 10: 1821 (+3)

11% more capital invested

Capital invested by funds: $9.17B → $10.2B (+$994M)

1.23% more ownership

Funds ownership: 128.67%129.89% (+1.2%)

1% more funds holding

Funds holding: 761769 (+8)

11% less repeat investments, than reductions

Existing positions increased: 240 | Existing positions reduced: 270

16% less call options, than puts

Call options by funds: $2.8B | Put options by funds: $3.33B

Holders
769
Holders Change
+8
Holders Change %
+1.05%
% of All Funds
11.04%
Holding in Top 10
21
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+16.67%
% of All Funds
0.3%
New
88
Increased
240
Reduced
270
Closed
73
Calls
$2.8B
Puts
$3.33B
Net Calls
-$526M
Net Calls Change
+$836M
Name Holding Trade Value Shares
Change
Change in
Stake
AW
426
Alaethes Wealth
Nevada
$507K -$45.2K -460 -8%
ACM
427
Advisors Capital Management
New Jersey
$505K +$3.63K +37 +0.7%
FNBT
428
FineMark National Bank & Trust
Florida
$505K -$14.7K -150 -3%
CA
429
Cornerstone Advisory
Maryland
$505K -$156K -1,586 -24%
SCA
430
Snowden Capital Advisors
New York
$504K -$13.7K -139 -3%
EFS
431
Essex Financial Services
Connecticut
$502K +$252K +2,568 +101%
MOS
432
MGO One Seven
Ohio
$502K -$5.6K -57 -1%
JCM
433
Jacobi Capital Management
Pennsylvania
$501K -$25.3K -257 -5%
ECM
434
Evergreen Capital Management
Washington
$500K
SAM
435
Seelaus Asset Management
New Jersey
$496K -$21.3K -217 -4%
EWA
436
EP Wealth Advisors
California
$495K -$89.7K -913 -15%
IC
437
IEQ Capital
California
$492K +$98 +1 +0%
ISL
438
Ingalls & Snyder LLC
New York
$491K
RCAG
439
Rehmann Capital Advisory Group
Michigan
$489K
MCA
440
Millennium Capital Advisors
Arkansas
$489K +$4.32K +44 +0.9%
HDIM
441
Hanson & Doremus Investment Management
Vermont
$487K -$283K -2,877 -37%
RFA
442
Resurgent Financial Advisors
Georgia
$486K -$33.7K -343 -7%
BBHC
443
Brown Brothers Harriman & Co
New York
$485K
WAP
444
Wealthcare Advisory Partners
Pennsylvania
$483K +$124K +1,260 +35%
HL
445
HeadInvest LLC
Maine
$470K +$35.6K +362 +8%
SIG
446
Sargent Investment Group
Maryland
$459K
MC
447
Moors & Cabot
Massachusetts
$458K -$226K -2,300 -33%
PMG
448
ProVise Management Group
Florida
$458K +$29.6K +301 +7%
SRC
449
Shufro Rose & Co
New York
$456K
SIC
450
Salem Investment Counselors
North Carolina
$455K -$24.6K -250 -5%

XBI Hedge Fund Activity: Q3 2024 in Review

769 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q3 2024, worth a combined $10.2B — up 11% from $9.17B a quarter earlier.

Buyers outnumbered sellers: 88 funds opened new XBI positions and 73 closed out — a net gain of 15 holders — while 240 added to existing stakes and 270 trimmed.

The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, adding an estimated $603M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $281M sold.

  • 769 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q3 2024, up from 761 in Q2 2024.
  • Funds reported $10.2B of State Street SPDR S&P Biotech ETF stock for Q3 2024, up 11% quarter-over-quarter.
  • 88 funds opened new State Street SPDR S&P Biotech ETF positions in Q3 2024 and 73 closed out, a net change of +15 holders.
  • The largest State Street SPDR S&P Biotech ETF buyer in Q3 2024 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $603M added.
  • The largest State Street SPDR S&P Biotech ETF seller in Q3 2024 was Avoro Capital Advisors, an estimated $281M sold.

Based on aggregated 13F filings for Q3 2024.